Correspondence 0001193125-24-151734 from Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972) (CGEM)
Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972)
Date: May 31, 2024 · CIK: 0001789972 · Accession: 0001193125-24-151734
AI Filing Summary & Sentiment
File numbers found in text: 333-279452
Show Raw Text
CORRESP 1 filename1.htm CORRESP CULLINAN THERAPEUTICS, INC. One Main Street, Suite 1350 Cambridge, MA 02142 May 31, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tamika Sheppard Re: Cullinan Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-279452) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cullinan Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on June 4, 2024, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please call Thomas Danielski of Ropes & Gray LLP, counsel to the Company, at (617) 235-4961 as soon as the registration statement has been declared effective. [Signature page follows] Very truly yours, CULLINAN THERAPEUTICS, INC. By: /s/ Mary Kay Fenton Name: Mary Kay Fenton Title: Chief Financial Officer [Signature Page to Acceleration Request]